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Abstract
Objectives: Our study had two objectives: a) to systematically identify all existing systematic reviews of Chinese herbal
medicines (CHM) published in Cochrane Library; b) to assess the methodological quality of included reviews.
Methodology/Principal Findings: We performed a systematic search of the Cochrane Database of Systematic Reviews (CDSR,
Issue 5, 2010) to identify all reviews of CHM. A total of fifty-eight reviews were eligible for our study. Twenty-one of the
included reviews had at least one Traditional Chinese Medicine (TCM) practitioner as its co-author. 7 reviews didn’t include
any primary study, the remaining reviews (n=51) included a median of 9 studies and 936 participants. 50% of reviews were
last assessed as up-to-date prior to 2008. The questions addressed by 39 reviews were broad in scope, in which 9 reviews
combined studies with different herbal medicines. For OQAQ, the mean of overall quality score (item 10) was 5.05 (95% CI;
4.58-5.52). All reviews assessed the methodological quality of primary studies, 16% of included primary studies used
adequate sequence generation and 7% used adequate allocation concealment. Of the 51 nonempty reviews, 23 reviews
were reported as being inconclusive, while 27 concluded that there might be benefit of CHM, which was limited by the poor
quality or inadequate quantity of included studies. 58 reviews reported searching a median of seven electronic databases,
while 10 reviews did not search any Chinese database.
Conclusions: Now CDSR has included large numbers of CHM reviews, our study identified some areas which could be
improved, such as almost half of included reviews did not have the participation of TCM practitioners and were not up-to-
date according to Cochrane criteria, some reviews pooled the results of different herbal medicines and ignored the
searching of Chinese databases.
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Introduction
Traditional Chinese Medicine (TCM) is an essential part of the
healthcare system in several Asian countries, and is considered a
complementary or alternative medical system in most Western
countries [1]. Chinese herbal medicines (CHM) are an essential
part of TCM [2]. The 2002 National Health Interview Survey
showed that 18.6% of adults used CHM in the United States,
while it was 12.1% in 1997 [3]. With the increased use of CHM,
questions arise from clinicians, patients, and policymakers as to the
effectiveness of these interventions [4]. In an era of evidence-based
healthcare, systematic reviews of randomized controlled trials
(RCTs) are becoming increasingly important as a source of
evidence for decision-making. As the number of systematic reviews
of CHM increase, the quality of which has been highlighted and
called into question. Some studies have assessed the quality of
CHM reviews published in Chinese journals, in general, they have
been criticized for lacking a comprehensive search for clinical
trials, ignoring the characteristics of TCM, using inappropriate
criteria to assess the methodological quality of included studies,
and addressing too broadly defined questions [5–7]. All [8] these
aspects could have contributed to a poor quality review.
The Cochrane Collaboration is an international organization
that aims to prepare and maintain rigorous systematic reviews in
order to help people make well-informed decisions about health
care [8]. Compared with reviews published in paper-based
journals, Cochrane reviews are noted to have greater methodo-
logical quality [9]. Ever since 1999 when the first Cochrane review
of CHM was published, a sharp increase has been observed in the
number of similar reviews. However, no previous studies have
systematically assessed the methodological quality of Cochrane
reviews of CHM. Therefore, we did this overview of systematic
reviews. Our study had two objectives: a) to systematically identify
all existing Cochrane reviews of CHM; b) to assess the
methodological quality of included reviews.
Methods
Ethics
Data for this study was acquired through previously published
work, no patient or hospital data was accessed. Therefore, written
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28696consent and institutional ethical review was not required for this
research. The PRISMA checklist and flow diagram are available
as supporting information; see PRISMA Checklist S1 and
PRISMA Flow Diagram S1.
Literature search
In order to identify reviews focusing on CHM, we searched the
titles and abstracts of all reviews contained within the Cochrane
Database of Systematic Reviews (CDSR) (Issue 5, 2010) using the
following terms: Chinese or herb* or traditional or plant or medic*.
Inclusion and exclusion criteria
We included all Cochrane reviews of CHM. Protocols and
reviews which have been withdrawn from publication were
excluded. We defined CHM as preparations derived from plants
or parts of plants (e.g. leaves, stems, buds, flowers, roots or tubers)
that grow in China and have been widely used for medical
purpose. CHM include single herbs (or extracts from single herbs)
and compound formulas of several herbs in all forms of
preparation formulation (e.g. oral liquid, tablet, capsule, pill,
powder, plaster or injection liquid). It should be noted that our
definition of CHM does not include plant-derived chemicals or
synthetic chemicals which contain constituents of plants. For
example, although Huperzia serrata has its origin in China,
according to our definition, Huperzine A does not belong to
CHM because it is a kind of alkaloid extracted from Huperzia
serrata. In addition, we only included reviews discussing herbs
which originated from China, reviews on herbs such as Passiflora
and Echinacea, both of American origin, were invariably
excluded.
Oxman-Guyatt Overview Quality Assessment
Questionnaire (OQAQ) [10]
The OQAQ instrument was selected as the quality appraisal
tool, which was designed to evaluate whether the authors of a
systematic review conducted a comprehensive search, minimized
bias in the selection of primary studies, evaluated the primary
literature, and pooled the results appropriately. It consists of 10
questions, the first 9 questions are designed to assess different
aspects of methodological quality and have set answers of ‘‘yes’’,
‘‘partially/can’t tell’’, or ‘‘no’’, question 10 is an assessment of the
overall scientific quality of the systematic review on a scale of 1 to
7, it is answered based on how well the review scored on the first 9
questions.
Data extraction
We established a database (using Microsoft Excel 2007) to
extract data. The database had two components: 1) general
characteristics, including country of first author and number of
authors, whether the review had the participation of TCM
practitioners, number of trials and participants included, disease,
the year of review last assessed as up-to-date, conclusions drawn by
the reviewers (by assessing the reviewers’ abstract conclusions
statements), interventions in experimental groups, number of
herbs included, and whether the results of different herbal
medicines were pooled; 2) methodological quality of included
reviews, including OQAQ scale, the approach to assessment of
methodological quality of primary studies, the number of trials
with adequate sequence generation and allocation concealment,
and type and number of English and Chinese databases searched.
Two reviewers (Jing Hu and Wei Zhao) independently extracted
the information of each review, disagreements between the two
reviewers were resolved by discussion.
The questions addressed by a review may be broad or narrow in
scope, each review was assigned into one of the following two
categories: 1) narrowly focused reviews, intervention in each
review was single herb or herbal preparation, as an example of
‘‘Chinese herbal medicine suxiao jiuxin wan for angina pectoris’’;
2) broadly focused reviews, including reviews concerned multiple
Chinese herbs or a family of herbal medicines sharing similar
efficacy, such as ‘‘Chinese herbal medicine for premenstrual
syndrome’’ and ‘‘Chinese herbal medicine Huangqi type formu-
lations for nephrotic syndrome’’. For broadly focused reviews, we
listed the number of herbs included and assessed whether the
results of different herbal medicines were pooled.
A review was believed to have the participation of TCM
practitioners if at least one author works in TCM department,
university or hospital, or it stated that it had got suggestion from
TCM practitioners.
When we assessed the type and number of English and Chinese
databases searched, we only listed the databases which at least 4
reviews searched. In addition, the Cochrane Specialized Register
and databases/websites for ongoing trials were also searched in
some reviews, we did not list them in our study.
Results
278 potentially relevant reviews were obtained, after selection
(according to inclusion and exclusion criteria), a total of 58
Cochrane reviews [11–68] were eligible for our study, a full list of
reviews is included in Table S1. Of the 58 reviews, one review [49]
included herbs originated in China, India and Japan; interventions
in another review [55] concerned both herbal and chemical
medicines. In these two cases, we extracted and analyzed the
information relating to CHM.
General characteristics of included reviews
The number of authors in the 58 reviews ranged from 1 to 10,
the first authors were most often from China (46 [79%]), followed
by UK (n=8), and Netherlands, Canada, USA and Australia each
have one first-authored review. Twenty-one (36%) of the included
reviews had at least one TCM practitioner as its co-author. 7
(12%) reviews didn’t include any primary study, of the remaining
reviews (n=51), a total of 671 studies and 75,609 participants
were included, the median number of studies and participants
included were 9 (Quartile: 3, 15) and 936 (Quartile: 492, 1567)
respectively. 50% of the reviews were last assessed as up-to-date
prior to 2008, of reviews considered out-of-date, one was last
updated in 2000. In total, 44 diseases were investigated in the
included reviews, 18 (31%) reviews addressed cerebral vascular
and cardiovascular diseases (9 reviews focused on stroke), followed
by reviews focused on respiratory diseases (n=6) and gynecolog-
ical/pregnancy diseases (n=6).
Of the 51 nonempty reviews, only one review concluded
positively, 27 (53%) concluded that there might be benefit of
CHM for treating specific health conditions, which was limited by
the poor quality or inadequate quantity of studies, 23 (45%)
reviews concluded that the currently available data do not allow
any conclusion to be drawn, generally because of low methodo-
logical quality of studies, small number of studies and participants
included or publication bias.
Nineteen reviews focused on 13 single herbs or herbal
preparations, while the remainder (39 [67%]) addressed broad
questions, in which 34 reviews concerned multiple Chinese herbs
or multiple formulations of Chinese herbs, 5 reviews involved a
family of herbal medicines sharing similar efficacy, including
Huangqi type formulations (including Huangqi injection and
Cochrane Reviews of Chinese Herbal Medicines
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Nao-an capsule, Xifeng wan and Apoplexy Preventing Dry
Ointment Powder), Dan Shen agents (including Compound
Danshen Dripping Pill, Compound Danshen injection, Danshen
injection, Yiqi huoxue injection, and Quyu huatan xiezhuo fang)
and Sanchi (including Xinnaotai, Sanchitongshu capsule, Naom-
ing injection, Xuesaitong soft capsule, Sanqitongshu capsule,
Xuesaitong and Xueshuantong injection). Of the 39 reviews, 4
didn’t include any primary study, of the remaining reviews
(n=35), the median number of herbal medicines involved was 6
within a range of 1 to 71, results of different herbal medicines were
pooled in 9 reviews, in which 7 reviews pooled the results of all
Chinese herbal medicines, one review pooled all Danshen agents,
and one pooled Sanchi.
Methodological quality of included reviews
Table 1 presents a summary of OQAQ items of the included
reviews, the mean score (item 10) was 5.05, 95% CI (4.58, 5.52).
41 of 58 reviews attempted to minimize bias during the selection of
studies by at least two reviewers independently select eligible
studies.
All reviews reported assessing the methodological quality of
included primary studies, 21 (36%) reviews used the Cochrane
Collaboration’s ‘Risk of Bias’ tool, the Jadad scale was used in 6
reviews, 12 (21%) reviews used unnamed checklist. Among 671
included studies, 108 (16%) used adequate sequence generation,
allocation concealment was adequate in 50 (7%) studies.
The median number of databases searched in 58 reviews was 7
within a range of 4 to 15. Regarding to the English language
databases, the most searched was MEDLINE (98%), followed by
EMBASE (97%) and CENTRAL (97%). CBM was the most
searched Chinese database (78%), the second most used was
CNKI (45%) and the third was VIP (24%) (Table 2). All reviews
searched at least 2 English databases, while 10 reviews did not
search any Chinese database. 41 (71%) reviews searched at least 3
English databases, while only 6 (10%) reviews searched at least 3
Chinese databases (Table 3).
Discussion
Evidence-based health care involves the systematic collection,
synthesis and application of scientific evidence to guide clinical
practice and policy-making. Systematic reviews are a key
Table 1. Summary of OQAQ questions in included reviews.
OQAQ question Yes(%) Partially/Can’t tell(%) No(%)
1. Were the search methods used to find evidence reported? 58(100) 0(0) 0(0)
2. Was the search strategy for evidence reasonably comprehensive? 51(88) 1(2) 6(10)
3. Were the criteria used for deciding which studies to include reported? 58(100) 0(0) 0(0)
4. Was bias in the selection for studies avoided? 41(71) 13(22) 4(7)
5. Were the criteria used for assessing validity of included studies reported? 57(98) 1(2) 0(0)
6. Was the validity of included studies assessed using appropriate criteria? 56(97) 2(3) 0(0)
7. Were the methods used to combine the findings of studies reported? 49(84) 9(16) 0(0)
8. Were the Findings of studies combined appropriately? 48(83) 9(15) 1(2)
9. Were the conclusions made by authors supported by the reported data? 58(100) 0(0) 0(0)
10. How would you rate the scientific quality of this overview? 5.05(1.78)*, (95% CI: 4.58, 5.52)
OQAQ, Oxman-Guyatt Overview Quality Assessment Questionnaire.
*Mean (SD).
doi:10.1371/journal.pone.0028696.t001
Table 2. Databases searched in included reviews.
English databases searched
Number of
reviews (%)
n=58 Chinese databases searched
Number of
reviews (%)
n=58
MEDLINE* 57(98%) CBM(Chinese Biomedical Database) 45(78%)
CENTRAL(The Cochrane Central Register of Controlled Trials) 56(97%) CNKI(China National Knowledge Infrastructure) 26(45%)
EMBASE 56(97%) VIP (a full text database of China) 14(24%)
AMED(Allied and Complementary Medicine Database) 28(48%) The Chinese Cochrane Centre Controlled Trials Register 11(19%)
Cochrane Complementary Medicine Field Trials Register 20(34%) TCMLARS(Traditional Chinese Medical Literature Analysis
and Retrieval System)
6(10%)
CINAHL(Cumulative Index to Nursing and Allied Health Literature) 15(26%)
LILACS(Latin American and Caribbean Health Science Literature) 11(19%)
SIGLE(System for Information on Grey Literature in Europe) 7(12%)
PsycINFO 4(7%)
*including two reviews which used PubMed.
doi:10.1371/journal.pone.0028696.t002
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included 58 systematic reviews of CHM.
Almost seventy percent of included reviews’ topics were too
broad, the percentage was much higher than that of similar
reviews published in Chinese journals, which was 38 percent (41
among 107 reviews) [69]. It is difficult to develop a comprehensive
search strategy for broadly focused reviews, for instance, one
hundred and sixty herbal medicines are now available for
coronary heart diseases treatment, a systematic review of CHM
for coronary heart disease will have to include clinical trials of all
these herbal medicines, it is easily to cause the incomplete
identification of relevant studies. Choosing broad topics for
reviews will require more resources in data collection and analysis,
the results may also be too complicated to interpret. So topic
selection of CHM reviews should focus on specific clinical
problems, the extensive titles are not recommended.
As broad questions of reviews may be addressed by large sets of
heterogeneous studies, the data synthesis may be particularly
challenging. In our study, 9 reviews (among the 39 broadly focused
reviews) pooled the results of different herbs, which did not identify
potentially important differences in effects across different
interventions. Systematic reviews can, but do not have to use
meta-analysis when combining data from primary studies, prior to
conducting a meta-analysis, reviewers should examine the
consistency of the interventions. It is recommended that the data
of each intervention should be analyzed and presented separately
if several different interventions for the same condition were tested
in one review.
The goal of a systematic review is to identify relevant studies
completely and unbiasedly [70]. It has been demonstrated [71,72]
that significant amounts of evidence would potentially be missed if
the search is limited to English-only sources. Because a
considerable number of clinical trials on CHM were published
only in the Chinese language journals, so a comprehensive search
of Chinese databases is essential for a systematic review of CHM.
However, we were disappointed to find that almost twenty percent
of reviews did not search any Chinese database in our study. One
study [73] compared four Chinese databases and concluded that
CBM is the preferred database for systematic reviewers to retrieve
relevant Chinese studies, while CNKI is recommended for non-
Chinese-speaking researchers due to its free searched English
version website (www.global.cnki.net) and ‘‘Cross-Language
Search’’ functions. CBM has no English website and a fee is
charged for searching, now many Chinese medical universities
have got the permission to search CBM, so maybe the most cost-
and time-efficient way to search it is to enhance collaboration with
Chinese researchers.
In doing a review of CHM, professional advice from TCM
practitioners is of great value. It is generally assumed that the
characteristics of TCM would be well taken into account in a
review if one or some of its reviewers majored in TCM. In our
study, we found that more than sixty percent of reviews did not
have one TCM practitioner in the authors list, which might lead to
insufficient consideration of the characteristics of TCM (e.g.
determination of treatment based on pathogenesis obtained
through differentiation of symptoms and signs) and incorrect
results. We suggest that future reviews should be authored by a
group of individuals with both clinical expertise and methodolog-
ical expertise.
Of the 671 primary studies included, less than twenty percent
of studies used adequate sequence generation, and only seven
percent used adequate allocation concealment. Because of the
poor methodological quality of primary studies, nearly half of
reviews were reported as being inconclusive, while 27 reviews
provided preliminary evidence of CHM’s benefits to certain
conditions, which should be considered tentative and need to be
confirmed with rigorous RCTs. The Chinese government has
been aware of the importance of conducting scientifically sound
RCTs and has made substantial investments into funding clinical
researches of CHM, now many well-designed RCTs of CHM
with rigorous methodology are in progress or have been
completed in China [74], we believe future updates of currently
inconclusive Cochrane reviews of CHM may reach more
definitive conclusions.
Limitations of the study
Although we believed a review has a greater chance of
considering the characteristics of TCM if at least one author
works in TCM department, university or hospital, or it stated that
it had got suggestion from TCM practitioners, it is quite possible
that some reviewers had consulted TCM experts while designing
and doing the review, but did not report it in articles. As cases of
this kind could not be ruled out, we therefore might have
underestimated the proportion of reviews getting support from
TCM practitioners. In addition, we restricted our search to
Cochrane reviews because they are generally less prone to bias
than systematic reviews published in paper-based journals
[9,75,76]. However, this might cause the results of this study to
be only applicable to review articles in the Cochrane database.
Further evaluation is needed in order to know whether the
systematic reviews of CHM published in English paper-based
journals even in the leading journals have the same problem.
Supporting Information
Table S1 List of all included Cochrane reviews of CHM.
(DOC)
PRISMA Checklist S1
(DOC)
PRISMA Flow Diagram S1
(DOC)
Table 3. Number of English and Chinese databases searched.
Number of English databases Number of reviews (%) n=58 Number of Chinese databases Number of reviews (%) n=58
0 0(0%) 0 10(17%)
1 0(0%) 1 15(26%)
2 2(3%) 2 19(33%)
3 15(26%) 3 8(14%)
.3 41(71%) .3 6(10%)
doi:10.1371/journal.pone.0028696.t003
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